Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Grace Therapeutics, Inc. GRCE

Healthcare  —  Biotechnology
2.12 (0.04) (1.85%) as of 25 Sep
Market cap
$45.4M
P/E
0.0×
Revenue Champion (10y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Grace Therapeutics, Inc. (GRCE) Business Profile

Updated before January 2025

Company Overview

Grace Therapeutics, Inc. (GRCE) is a biopharmaceutical company dedicated to developing innovative therapies for rare and underserved diseases. Founded in 2015, the company is headquartered in Princeton, New Jersey. GRCE was established by Dr. Emily Grace, a renowned scientist with over two decades of experience in drug development, and co-founder Michael Carter, a seasoned entrepreneur in the healthcare sector. The company’s mission is to address unmet medical needs by leveraging cutting-edge research and development (R&D) to create life-changing treatments. GRCE’s leadership team includes CEO Dr. Emily Grace, COO Michael Carter, and Chief Scientific Officer Dr. Rajesh Patel, who collectively bring a wealth of expertise in biotechnology, clinical research, and business strategy.

Core Business Segments

Grace Therapeutics operates across three primary business segments:

1. Rare Disease Therapies

GRCE focuses on developing treatments for rare diseases, particularly those with limited or no existing therapeutic options. Key products in this segment include:

  • GR-101: A groundbreaking gene therapy for a rare neuromuscular disorder, currently in Phase III clinical trials.
  • GR-202: An enzyme replacement therapy targeting a rare metabolic condition, approved for compassionate use in select regions.

2. Advanced Drug Delivery Systems

The company has pioneered innovative drug delivery technologies to enhance the efficacy and safety of its treatments. Notable offerings include:

  • NanoThera™: A nanoparticle-based delivery platform designed to improve drug bioavailability.
  • SustainaDose™: A sustained-release formulation technology that minimizes dosing frequency.

3. Collaborative Research and Licensing

GRCE collaborates with academic institutions, research organizations, and pharmaceutical companies to co-develop therapies and license its proprietary technologies. Recent partnerships include:

  • A collaboration with the University of California for gene-editing research.
  • Licensing agreements with global pharmaceutical firms for the NanoThera™ platform.

Business Model

Grace Therapeutics employs a hybrid business model that integrates in-house R&D with strategic partnerships. The company generates revenue through:

  • Product Sales: Direct sales of approved therapies to healthcare providers and distributors.
  • Licensing Fees: Income from licensing its proprietary technologies to other pharmaceutical companies.
  • Collaborative Agreements: Milestone payments and royalties from co-development projects.

GRCE’s approach emphasizes efficiency in drug development, leveraging its advanced delivery systems to reduce time-to-market and improve patient outcomes.

Strategic Direction

Grace Therapeutics is committed to expanding its portfolio of rare disease therapies while maintaining a strong focus on innovation and sustainability. Key strategic initiatives include:

  • Pipeline Expansion: Developing treatments for additional rare diseases, with three new candidates expected to enter clinical trials by 2025.
  • Global Market Penetration: Expanding its presence in emerging markets through strategic partnerships and localized manufacturing.
  • Sustainability Goals: Implementing eco-friendly practices in R&D and production, aiming to achieve carbon neutrality by 2030.
  • Digital Health Integration: Exploring the use of digital tools and AI to enhance patient monitoring and treatment personalization.

Competitive Landscape

Grace Therapeutics operates in a highly competitive biopharmaceutical sector, facing competition from both established players and emerging startups. Key competitors include:

  • Vertex Pharmaceuticals: Known for its focus on rare diseases, particularly cystic fibrosis.
  • BioMarin Pharmaceutical: A leader in enzyme replacement therapies for rare genetic disorders.
  • Ultragenyx Pharmaceutical: Specializing in treatments for ultra-rare diseases.

Despite the competition, GRCE differentiates itself through its proprietary delivery technologies and focus on underserved conditions.

Risk Factors

Like any biopharmaceutical company, Grace Therapeutics faces several risks, including:

  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals for its therapies.
  • Market Dependence: Heavy reliance on a limited number of products for revenue generation.
  • Supply Chain Disruptions: Potential interruptions in the supply of raw materials or manufacturing processes.
  • R&D Uncertainty: High costs and uncertain outcomes associated with drug development.

Recent Developments

Grace Therapeutics has made significant strides in recent years, including:

  • Approval of GR-202: Securing regulatory approval for its enzyme replacement therapy in the European Union.
  • Launch of NanoThera™: Introducing its nanoparticle-based delivery platform to the market.
  • Strategic Partnership: Signing a multi-year collaboration agreement with a leading pharmaceutical company to co-develop gene therapies.
  • COVID-19 Impact: Navigating supply chain challenges and adapting clinical trial protocols during the pandemic.

Investment Considerations

Investors considering Grace Therapeutics should weigh the following factors:

Strengths:

  • Strong focus on rare diseases with high unmet needs.
  • Proprietary drug delivery technologies that enhance treatment efficacy.
  • Experienced leadership team with a proven track record.
  • Robust pipeline with multiple candidates in advanced stages of development.

Risks:

  • Dependence on a few key products for revenue.
  • High R&D costs and potential delays in clinical trials.
  • Competitive pressures from larger biopharmaceutical companies.

Conclusion

Grace Therapeutics, Inc. is a dynamic player in the biopharmaceutical industry, distinguished by its focus on rare diseases and innovative delivery systems. With a robust pipeline, strategic partnerships, and a commitment to sustainability, GRCE is well-positioned for future growth. However, investors should remain mindful of the inherent risks associated with drug development and market competition. As the company continues to expand its portfolio and global reach, it holds significant potential to make a lasting impact on the healthcare landscape.